T1	intervention 23 31	eribulin
T2	outcome-Measure 1050 1081	progression-free survival (PFS)
T3	control 914 917	TPC
T6	total-participants 1259 1261	58
T7	total-participants 1288 1290	57
T8	intervention-participants 1300 1302	26
T9	control-participants 1316 1318	31
T10	outcome 1356 1366	median PFS
T11	iv-cont-median 1371 1381	6.6 months
T12	cv-cont-median 1403 1413	4.2 months
T15	outcome 1498 1508	Median TTF
T16	iv-cont-median 1513 1523	6.0 months
T17	cv-cont-median 1545 1555	3.6 months
T20	outcome 1684 1707	grade ≥ 3 adverse event
T21	outcome 1712 1723	neutropenia
T22	iv-bin-percent 1725 1730	22.2%
T23	cv-bin-percent 1752 1757	16.1%
T24	eligibility 558 704	Patients with recurrent HER2-negative BC previously receiving anthracycline and taxane AT-based chemotherapy in the adjuvant or first-line setting
T4	outcome-Measure 1112 1143	time to treatment failure (TTF)
T5	outcome-Measure 1145 1172	overall response rate (ORR)
T13	outcome-Measure 1174 1194	duration of response
T14	outcome-Measure 1200 1206	safety
